LGVN

Longeveron Inc

1.59

Oct 22 • 3:59 PM ET +0.16 (11.19%)

1.49

Aftermarket • 7:56 PM ET -0.10 (-6.29%)

Healthcare Biotechnology USA Nano NASD

Peers: MESO PLUR BCDA CELZ BRTX CAPR FBLG CELU LCTX VCEL

| Held by: VXF VTI

Scroll to Statements

Index	-
Market Cap	5.07M
Enterprise Value	-4.43M
Income	-23.47M
Sales	1.19M
Book/sh	3.28
Cash/sh	3.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	38
IPO	Feb 12, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	4.26
P/B	0.48
P/C	0.50
P/FCF	-
EV/EBITDA	-
EV/Sales	-3.72
Quick Ratio	2.63
Current Ratio	2.63
Debt/Eq	0.06
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-10.15
EPS next Y	-5.00
EPS next Q	-1.95
EPS this Y	39.92%
EPS next Y	35.48%
EPS next 5Y	58.83%
EPS past 3/5Y	47.61% 8.03%
Sales past 3/5Y	-0.63% -26.60%
EPS Y/Y TTM	20.66%
Sales Y/Y TTM	-42.74%
EPS Q/Q	42.21%
Sales Q/Q	-9.18%
Earnings	Aug 12 AMC
EPS/Sales Surpr.	-8.57% -11.96%

Insider Own	21.91%
Insider Trans	0.00%
Inst Own	21.72%
Inst Trans	0.45%
ROA	-145.64%
ROE	-203.61%
ROIC	-225.67%
Gross Margin	-15.92%
Oper. Margin	-1992.84%
Profit Margin	-1977.59%
SMA20	-26.56%
SMA50	-65.70%
SMA200	-76.49%
Trades

Shs Outstand	3.03M
Shs Float	2.49M
Short Float	4.29%
Short Ratio	1.07
Short Interest	0.11M
52W High	12.30 -87.07%
52W Low	1.31 21.37%
Volatility	12.10% 10.99%
ATR (14)	0.32
RSI (14)	27.09
Beta	-0.19
Rel Volume	0.73
Avg Volume	100.06K
Volume	73,527

Perf Week	6.00%
Perf Month	-38.85%
Perf Quarter	-73.50%
Perf Half Y	-83.72%
Perf YTD	-68.58%
Perf Year	-80.82%
Perf 3Y	-99.18%
Perf 5Y	-99.53%
Perf 10Y	-
Recom	3.00
Target Price	4.25
Prev Close	1.43
Price	1.59
Change %	11.19%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	ROTH MKM	Buy	$10

Sep-30-26 04:05PM	Longeveron to Participate in Three Longevity/Aging Investment Conferences (GlobeNewswire)
Sep-18-26 06:24AM	Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug (BioPharma Dive) -8.12%
Sep-16-26 05:27PM	Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire) -59.43%
Sep-03-26 09:15AM	Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-24-26 04:05PM	Longeveron Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -18.84%
04:05PM	Loading…
Aug-19-26 04:05PM	Longeveron Appoints Nirav Jhaveri as Chief Financial Officer (GlobeNewswire)
Aug-12-26 09:40PM	Longeveron Inc. Q2 2026 Earnings Call Summary (Moby) +7.92% -6.60%
04:05PM	Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-11-26 09:28AM	Earnings To Watch: Longeveron Inc (LGVN) Q2 2026 -- GF Value Sees 58% Downside (GuruFocus.com) -6.00%
09:05AM	Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition (GlobeNewswire)
Aug-03-26 04:05PM	Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 (GlobeNewswire)
Jul-23-26 09:15AM	Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors (GlobeNewswire)
Jul-13-26 07:05AM	Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease (GlobeNewswire) -6.52%
Jul-06-26 04:05PM	Longeveron Appoints Marie Washburn as Chief Financial Officer (GlobeNewswire) -5.94%
Jun-18-26 09:20AM	New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) (GlobeNewswire)
09:20AM	Loading…
Jun-09-26 09:20AM	Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) (GlobeNewswire)
Jun-04-26 09:15AM	Longeveron to Present at BIO International Convention 2026 (GlobeNewswire)
May-20-26 04:05PM	Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities (GlobeNewswire)
May-14-26 08:30AM	Longeveron Inc. Q1 2026 Earnings Call Summary (Moby) -6.94%
May-13-26 04:05PM	Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
May-11-26 09:10AM	Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire)
May-08-26 04:05PM	Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire)
May-05-26 04:15PM	Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026 (GlobeNewswire)
Apr-10-26 09:55AM	Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells (PR Newswire)
Apr-08-26 09:15AM	Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) (GlobeNewswire)
Mar-18-26 10:00AM	A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. (PR Newswire)
08:30AM	Longeveron Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-17-26 04:05PM	Longeveron Announces 2025 Full Year Financial Results and Provides Business Update (GlobeNewswire) +8.14%
Mar-16-26 09:21AM	Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results (GuruFocus.com) -8.81%
Mar-12-26 09:00AM	Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 (GlobeNewswire)
04:05PM	Loading…
Mar-11-26 04:05PM	Longeveron Announces Closing of Private Placement of up to $30 Million (GlobeNewswire) -8.81%
09:00AM	A $30 Million Reason to Buy Penny Stock Longeveron Today (Barchart)
Mar-10-26 03:58PM	Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal (Benzinga) +68.27%
09:00AM	Longeveron Announces Private Placement of up to $30 Million (GlobeNewswire)
Mar-03-26 10:02AM	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (PR Newswire)
Feb-25-26 11:05AM	Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell (GlobeNewswire) -5.63%
Feb-13-26 04:30PM	Longeveron Appoints Stephen H. Willard as Chief Executive Officer (GlobeNewswire)
Feb-05-26 09:15AM	Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program (GlobeNewswire) -5.34%
Jan-29-26 09:15AM	Longeveron Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) (GlobeNewswire)
Jan-26-26 09:15AM	Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire) +6.17%
Dec-29-25 09:15AM	Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 (GlobeNewswire)
Dec-17-25 09:15AM	Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy (GlobeNewswire) +7.81%
Dec-03-25 09:15AM	Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum (GlobeNewswire)
Dec-02-25 09:15AM	Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging (GlobeNewswire)
Dec-01-25 12:00PM	Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) (GlobeNewswire) -5.08%
Nov-19-25 09:15AM	Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) (GlobeNewswire)
Nov-12-25 09:05AM	Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy (GlobeNewswire)
Nov-04-25 04:05PM	Longeveron Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-25 08:15AM	Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2025 Result (GuruFocus.com)
Oct-28-25 09:15AM	Longeveron to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (GlobeNewswire)
Oct-27-25 09:15AM	Longeveron Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect (GlobeNewswire)
Oct-06-25 09:15AM	Longeveron to Participate in the 4th Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Oct-01-25 04:05PM	George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron Board of Directors (GlobeNewswire)
Sep-22-25 09:15AM	Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-03-25 04:05PM	Longeveron Announces Key Leadership Updates (GlobeNewswire) -8.31%
Aug-29-25 07:25AM	Longeveron (LGVN) Secures Rights to Stem Cell Patent for Cardiac Treatment (Insider Monkey)
Aug-20-25 09:15AM	Longeveron to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 04:05PM	Longeveron Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +26.38% -12.19%
Aug-12-25 09:44AM	Longeveron Inc (LGVN) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-11-25 04:15PM	Longeveron Announces Closing Of Up To $17.5 Million Public Offering (GlobeNewswire)
Aug-08-25 01:28PM	Longeveron Announces Up To $17.5 Million Public Offering (GlobeNewswire) -46.62%
Aug-05-25 09:15AM	Longeveron to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 (GlobeNewswire) -9.36%
Jul-21-25 09:15AM	Longeveron Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease (GlobeNewswire) +10.53%
Jul-08-25 09:15AM	Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) (GlobeNewswire) +28.68%
Jun-26-25 09:05AM	Longeveron Appoints Than Powell as Chief Business Officer (GlobeNewswire)
Jun-24-25 06:30AM	Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire) +7.83%
Jun-09-25 09:15AM	Longeveron to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
May-20-25 09:15AM	Longeveron to Attend BIO International Convention 2025 (GlobeNewswire)
May-12-25 07:15AM	Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient (GlobeNewswire) +9.70%
May-08-25 04:05PM	Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -10.07%
May-02-25 08:30AM	Longeveron to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 (GlobeNewswire)
Apr-22-25 04:05PM	Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 (GlobeNewswire)
Mar-20-25 09:00AM	Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease (GlobeNewswire)
Mar-11-25 08:30AM	Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B ) in Alzheimer's Disease (GlobeNewswire) +5.44%
Mar-05-25 09:25AM	Longeveron to Present at the 37th Annual Roth Conference (GlobeNewswire) +5.26%
Feb-28-25 04:04PM	Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.21%
Feb-21-25 08:30AM	Longeveron to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 (GlobeNewswire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire) +5.06%
Feb-18-25 09:25AM	Longeveron Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B (GlobeNewswire) -5.39%
Feb-14-25 09:05AM	Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 (GlobeNewswire) +6.37%
Dec-18-24 09:10AM	Longeveron to Present at Biotech Showcase 2025 (GlobeNewswire) -7.30%
Dec-07-24 05:20AM	Longeveron initiated with a Buy at Roth MKM (TipRanks)
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 09:05AM	Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 (GlobeNewswire)
Nov-12-24 04:05PM	Longeveron Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.99% -7.83%
Nov-11-24 09:05AM	Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) (GlobeNewswire)
Nov-04-24 04:05PM	Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (GlobeNewswire) +6.40%
Oct-29-24 10:00AM	Longeveron Presents Lomecel-B Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) (GlobeNewswire)
Oct-27-24 03:10PM	Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting (GlobeNewswire)
Oct-14-24 09:05AM	Longeveron Lomecel-B Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) (GlobeNewswire) +8.38%
Oct-09-24 09:05AM	Longeveron Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting (GlobeNewswire)
Oct-07-24 09:05AM	Longeveron to Present at the UBS Virtual Organ Restoration and Cell Therapy Day (GlobeNewswire)
Oct-02-24 09:05AM	Longeveron to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-26-24 09:05AM	Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-03-24 09:00AM	Longeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire)
Aug-26-24 04:05PM	Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.23% -5.39%
Aug-14-24 04:05PM	Longeveron Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.75%
Aug-05-24 04:05PM	Longeveron to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire) -8.30% +9.06%
Jul-28-24 04:51PM	Longeveron Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B in Mild Alzheimer's Disease at the Alzheimer's Association International Conference (AAIC) (GlobeNewswire)

Show Previous News

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

M.D.Dr. Joshua Michael Hare FACC

General Counsel & SecretaryMr. Paul T. Lehr J.D.

CEO & DirectorMr. Stephen H. Willard Esq.

M.B.A.Mr. Nirav Suresh Jhaveri C.F.A.

CTO and Senior VP of ChemistryMr. Devin Blass

LGVN

Longeveron Inc

Upgrade your Finviz experience